Advances in Cryoprotectants: Antifreeze Peptide AVD Effectively Inhibits Ice Crystal Damage with 95.7% Cell Recovery Rate
Release time:
2025-06-05
In the field of cryopreservation of biological samples, ice crystal damage remains a core issue causing cell membrane rupture and functional loss. Traditional cryoprotectants like dimethyl sulfoxide (DMSO) exhibit cytotoxicity, while natural antifreeze proteins face challenges in large-scale application due to cost and immunogenicity.
Recently, a research team from Tianjin University published a study in Engineering, designing a novel antifreeze peptide, AVD, by mimicking the "molecular Lego" of Antarctic bacterial antifreeze proteins. Experiments show that frozen cells supplemented with AVD achieved a recovery rate of up to 95.7%, tripling the efficiency of conventional methods. This technology may offer key solutions for organ cryopreservation, cell therapy, and related fields.
Decoding the Antifreeze Mechanism: Inspiration from Antarctic Bacteria
Antarctic ice-edge bacteria evolved antifreeze proteins (IBPs) to withstand extreme cold. Their periodically arranged hook-like domains form molecular complementarity with ice crystal lattices. Research indicates that such proteins construct dynamic barriers at the ice-water interface via topological matching mechanisms, effectively inhibiting heterogeneous nucleation of ice crystals. However, natural antifreeze proteins suffer from high costs and immune rejection.
The team screened 51 samples containing repetitive motifs from 233 antifreeze proteins. Through phylogenetic analysis and molecular dynamics simulations, they identified key amino acid arrangement patterns. "It's like deciphering nature’s antifreeze code to find the most efficient molecular combination," explained Zhang Lei, the paper’s corresponding author.
AVD Design: Building an Ice Crystal Shield with "Molecular Lego"
The final AVD peptide chain contains only 20 amino acids. Its core features two key sites—Thr6 and Asn8—spaced 7.8 Å apart (about 1/100,000th of a hair’s diameter), precisely matching the oxygen atom spacing on ice crystal prism planes. Molecular simulations show AVD embeds into ice growth interfaces, reducing ice crystal growth speed by 60%. Ingeniously, the Ser18 site forms an "auxiliary lock" via hydrogen bonds, enhancing binding stability by 40%. At a concentration of just 1 mg/mL, AVD achieves 86% of natural antifreeze proteins’ ice-inhibition efficacy.
Cryoprotection Validation: Cell Recovery Rate Soars from 30% to 95%
At -80°C, AVD demonstrated dual protective mechanisms: suppressing ice growth while stabilizing calcium ion channels in cell membranes. Lung cancer cells (GLC-82) frozen with AVD showed a 95.7% recovery rate—3.1 times higher than untreated groups. Immune cells (RAW264.7) surged from 2.4% to 34.9% recovery. Microscopy revealed intact mitochondrial structures in AVD-protected cells, with proliferation capacity matching fresh cells. "It’s like dressing cells in nano-scale antifreeze suits, shielding against external ice puncture while maintaining internal ion balance," Zhang analogized.
Despite AVD’s efficacy, industrialization faces challenges. Current chemical synthesis costs ~¥500 per gram, while freezing one cell sample requires 10 mg (¥5/sample). In contrast, DMSO costs merely ¥0.1. The team is developing biosynthetic processes aiming to slash costs by 80%. Additionally, AVD’s protective effects on specialized cells (e.g., cardiomyocytes) require further validation.
"This study pioneers precision antifreeze design at the molecular scale, offering a groundbreaking solution for long-term organ preservation," commented Prof. Boris Rubinsky, President of the Society for Cryobiology.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
